EARLY FINDINGS FROM PROLIA (R) POST-MARKETING SAFETY SURVEILLANCE FOR ATYPICAL FEMORAL FRACTURE, OSTEONECROSIS OF THE JAW, SEVERE SYMPTOMATIC HYPOCALCEMIA, AND ANAPHYLAXIS